M&A Speculation: Recent regulatory filings updating executive severance and change-of-control provisions have sparked renewed talk of potential acquisitions. Market participants highlight how such adjustments often precede strategic deals in the biotech space. The stock has rallied sharply on the back of these developments.
Trial Momentum: Discussions center on the ongoing REGAL Phase 3 study for the company's lead immunotherapy candidate. Observers note that some patients have remained on treatment well beyond initial projections, underscoring promising durability signals. This progress is viewed as a key catalyst ahead of final data readout.
Short Interest Focus: Elevated short positions have prompted commentary on the possibility of a squeeze if buying accelerates. Participants point to high borrow fees as adding to the pressure. The tone remains one of measured anticipation around near-term events.
Note: This discussion summary was generated from an AI condensation of post data.
Sellas Life Sciences Hedge Fund Activity
We have seen 120 institutional investors add shares of Sellas Life Sciences stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 6,208,185 shares (+283.7%) to their portfolio in Q1 2026, for an estimated $26,260,622
- ANSON FUNDS MANAGEMENT LP removed 6,032,938 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,744,176
- BLACKROCK, INC. added 4,657,356 shares (+61.8%) to their portfolio in Q1 2026, for an estimated $19,700,615
- VANGUARD GROUP INC added 1,627,495 shares (+23.8%) to their portfolio in Q4 2025, for an estimated $6,135,656
- JONES FINANCIAL COMPANIES LLLP added 1,245,834 shares (+290.2%) to their portfolio in Q1 2026, for an estimated $5,269,877
- MILLENNIUM MANAGEMENT LLC removed 1,228,325 shares (-88.5%) from their portfolio in Q1 2026, for an estimated $5,195,814
- GEODE CAPITAL MANAGEMENT, LLC added 835,269 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $3,533,187
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
